Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
After finishing at $6.17 in the prior trading day, Recursion Pharmaceuticals Inc (NASDAQ: RXRX) closed at $5.92, down -4.05%. In other words, the price has decreased by -$4.05 from its previous closing price. On the day, 4.56 million shares were traded. RXRX stock price reached its highest trading level at $6.3 during the session, while it also had its lowest trading level at $5.895.
Ratios:
Our goal is to gain a better understanding of RXRX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.07 and its Current Ratio is at 6.07. In the meantime, Its Debt-to-Equity ratio is 0.15 whereas as Long-Term Debt/Eq ratio is at 0.13.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Morgan Stanley on May 22, 2023, initiated with a Equal-Weight rating and assigned the stock a target price of $8.
On March 16, 2023, Needham started tracking the stock assigning a Buy rating and target price of $17.
On September 16, 2022, KeyBanc Capital Markets started tracking the stock assigning a Overweight rating and target price of $20.KeyBanc Capital Markets initiated its Overweight rating on September 16, 2022, with a $20 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 05 ’24 when Gibson Christopher sold 20,000 shares for $6.14 per share. The transaction valued at 122,800 led to the insider holds 762,656 shares of the business.
Gibson Christopher sold 20,000 shares of RXRX for $120,800 on Sep 04 ’24. The Chief Executive Officer now owns 762,656 shares after completing the transaction at $6.04 per share. On Sep 03 ’24, another insider, Borgeson Blake, who serves as the Director of the company, sold 11,447 shares for $6.27 each. As a result, the insider received 71,718 and left with 7,121,322 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RXRX now has a Market Capitalization of 1670849024 and an Enterprise Value of 1278867200. For the stock, the TTM Price-to-Sale (P/S) ratio is 33.67 while its Price-to-Book (P/B) ratio in mrq is 2.85. Its current Enterprise Value per Revenue stands at 25.765 whereas that against EBITDA is -3.504.
Stock Price History:
Over the past 52 weeks, RXRX has reached a high of $15.74, while it has fallen to a 52-week low of $4.97. The 50-Day Moving Average of the stock is -19.90%, while the 200-Day Moving Average is calculated to be -34.73%.
Shares Statistics:
The stock has traded on average 5.70M shares per day over the past 3-months and 5160390 shares per day over the last 10 days, according to various share statistics. A total of 226.26M shares are outstanding, with a floating share count of 215.41M. Insiders hold about 23.68% of the company’s shares, while institutions hold 77.36% stake in the company. Shares short for RXRX as of 1723680000 were 54147202 with a Short Ratio of 9.49, compared to 1721001600 on 49327170. Therefore, it implies a Short% of Shares Outstanding of 54147202 and a Short% of Float of 26.75.
Earnings Estimates
The stock of Recursion Pharmaceuticals Inc (RXRX) is currently in the spotlight, with 7.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is -$0.47, with high estimates of -$0.38 and low estimates of -$0.8.
Analysts are recommending an EPS of between -$1.46 and -$2.0 for the fiscal current year, implying an average EPS of -$1.62. EPS for the following year is -$1.79, with 8.0 analysts recommending between -$1.26 and -$3.2.
Revenue Estimates
7 analysts predict $30.04M in revenue for the current quarter. It ranges from a high estimate of $44.6M to a low estimate of $11M. As of the current estimate, Recursion Pharmaceuticals Inc’s year-ago sales were $10.53MFor the next quarter, 7 analysts are estimating revenue of $14.67M. There is a high estimate of $20M for the next quarter, whereas the lowest estimate is $8M.
A total of 9 analysts have provided revenue estimates for RXRX’s current fiscal year. The highest revenue estimate was $88.3M, while the lowest revenue estimate was $44.61M, resulting in an average revenue estimate of $69.2M. In the same quarter a year ago, actual revenue was $44.58MBased on 8 analysts’ estimates, the company’s revenue will be $90.76M in the next fiscal year. The high estimate is $254.9M and the low estimate is $46.1M.
